FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:754-758 February 16, 2006 Number 7 Next

Inhibition of Tumor Necrosis Factor for Refractory Asthma

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Berry, M. A. PubMed Citation

Tumor necrosis factor (TNF), originally discovered and named on the basis of its tumor regression activity, is an important cytokine that regulates the pathogenetic mechanisms of chronic inflammatory diseases.^1,2 The translation of research findings to patient care resulted in the first successful cytokine-specific targeted therapies, the TNF inhibitors. Currently available inhibitors include the monoclonal antibodies against TNF-, infliximab and adalimumab, and the soluble TNF receptor fused to human IgG, etanercept.^1,2 Agents that block TNF- suppress inflammation, slow disease progression, and in some cases, induce remission in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and Crohn's disease.² In this issue . . . [Full Text of this Article]

Source Information

From the Departments of Pathobiology and Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, Cleveland.

This article has been cited by other articles:

• Guedes, A. G. P., Jude, J. A., Paulin, J., Kita, H., Lund, F. E., Kannan, M. S. (2008). Role of CD38 in TNF-{alpha}-induced airway hyperresponsiveness. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L290-L299 [Abstract] [Full Text]  
• Jude, J. A., Wylam, M. E., Walseth, T. F., Kannan, M. S. (2008). Calcium Signaling in Airway Smooth Muscle. Proc Am Thorac Soc 5: 15-22 [Abstract] [Full Text]  
• Qian, M., Bai, S. A., Brogdon, B., Wu, J.-T., Liu, R.-Q., Covington, M. B., Vaddi, K., Newton, R. C., Fossler, M. J., Garner, C. E., Deng, Y., Maduskuie, T., Trzaskos, J., Duan, J. J.-W., Decicco, C. P., Christ, D. D. (2007). Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor {alpha}-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans. Drug Metab. Dispos. 35: 1916-1925 [Abstract] [Full Text]  
• Moore, W. C., Peters, S. P. (2007). Update in Asthma 2006. Am. J. Respir. Crit. Care Med. 175: 649-654 [Full Text]  
• Adiseshaiah, P., Kalvakolanu, D. V., Reddy, S. P. (2006). A JNK-Independent Signaling Pathway Regulates TNF{alpha}-Stimulated, c-Jun-Driven FRA-1 Protooncogene Transcription in Pulmonary Epithelial Cells. J. Immunol. 177: 7193-7202 [Abstract] [Full Text]  
• Erin, E. M., Leaker, B. R., Nicholson, G. C., Tan, A. J., Green, L. M., Neighbour, H., Zacharasiewicz, A. S., Turner, J., Barnathan, E. S., Kon, O. M., Barnes, P. J., Hansel, T. T. (2006). The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-{alpha} in Asthma. Am. J. Respir. Crit. Care Med. 174: 753-762 [Abstract] [Full Text]